To reduce feeding intolerance among very low birth weight neonates.
INTRODUCTION
Feeding intolerance is common among very low birth weight (VLBW, <1500 g) neonates. 1, 2 As recently outlined by Jadcherla and Kliegman, 2 no uniform definition of feeding intolerance in the NICU exists, but its various manifestations are well known and include distended loops of bowel, emesis, large prefeeding gastric residuals, diarrhea, or gross blood in the stools. Feeding intolerance can prolong the need for parenteral nutrition and add to the length of hospitalization. 1, 2 Since the length of time parenteral nutrition is used in the NICU correlates with the likelihood of developing a nosocomial infection, improving feeding tolerance could diminish reliance on parenteral nutrition and thereby reduce nosocomial infections. 3 Many factors likely contribute to feeding intolerance among VLBW neonates. One factor is the disuse atrophy of the intestinal mucosa that can develop if a patient is fasted for several days. 4 We previously sought to reduce this mucosal atrophy in VLBW neonates by enterally administering a sterile, isotonic, noncaloric, growth factor-containing solution patterned after human amniotic fluid. [5] [6] [7] [8] [9] [10] [11] This experimental solution has the electrolyte composition of amniotic fluid and contains albumin and two enterocyte growth factors that are present in human amniotic fluid and approved by the US Food and Drug Administration (albeit for different indications); recombinant human erythropoietin and recombinant human granulocyte colony-stimulating factor. We reported that these factors are stable in this solution, 5 that the growth factors are relatively resistant to digestion, 6 that their cognate receptors are expressed on the luminal surface of fetal intestinal villi, 7, 8 and that the ingested growth factors are not absorbed into the blood but have a topical antiapoptotic action on enterocytes. 9, 10 We previously reported feasibility trials that indicated this solution could be given every 3 hours to VLBW neonates for a period of 72 hours. [11] [12] [13] However, it is likely that in a future randomized trial, needed to test the efficacy of the solution in preventing feeding intolerance, it would be administered for periods exceeding 3 days. We conducted the present study for two reasons, (1) to test the feasibility of administering this solution to VLBW neonates for up to 14 days, and (2) to obtain data on enteral caloric intake of recipients on which to base a subsequent randomized trial. Thus, we administered the test solution to 10 neonates and compared their enteral caloric intake during their first 3 weeks of life with that of 10 patients who met the study criteria but were born in the period immediately prior to initiation of the study.
MATERIALS AND METHODS Patients
Neonates were eligible for study if they had a birth weight of 750 to 1250 g, had a 5-minute Apgar score of 5 or more, and were deemed by the attending neonatologist as ''likely to survive''. Neonates were ineligible if they had proven or suspected chromosomal trisomy 13 or 18, had an obvious gastrointestinal tract malformation, or were judged as being too ill to be acceptable study candidates. This criterion was set as receiving mechanical ventilation with a FiO 2 > 0.50 at the time of study entry. The Institutional Review Boards of Intermountain Health Care and the University of South Florida approved the protocol and the parents of all enrolled patients who signed informed consents. A limited data set, from 10 consecutive neonates of 750 to 1250 g birth weight who did not receive the experimental solution because they were cared for in the period immediately preceding beginning the study, was obtained as deidentified existing data. The US Food and Drug Administration reviewed and approved this protocol and assigned the study the investigational new drug (IND) number 10844.
Study Procedures
The hospital pharmacists produced the experimental solution using sterile technique and the parenteral nutrition equipment in the manner previously reported. 5 The solution contained 115 meq/l sodium chloride, 17 meq/l sodium acetate, 4 meq/l potassium chloride, 225 ng/ml Neupogen (Filgrastim, Amgen Inc, Thousand Oaks, CA) and 4400 mU/ml Epoetin alfa (Epogen, Amgen). Human serum albumin (Baxter Health Care Corp, Hyland Division, Glendale, CA) was added to the infusion bag prior to adding the cytokines (the final concentration of albumin was 0.05%).
The pharmacist sent a full day's dose (eight syringes, each containing 2.5 ml/kg birth weight) to the NICU each study-day. The doses were kept in the refrigerator until used. Before administration, a syringe was placed near the patient in the isolet for 10 to 15 minutes to increase the temperature before it was given through the oral-gastric tube. When milk feedings were initiated the test solution was mixed with the milk. Once the enteral intake of milk reached 80 ml/kg/day the test solution was discontinued. We selected 80 ml/kg/day as a ''stop point'' to be consistent with our guideline that when a patient is tolerating this amount of milk we consider stopping central hyperalimentation. The test solution was given for a maximum of 14 days even if the patient failed to reach 80 ml/kg of milk feedings by that time.
Measurement of Enteral Caloric Intake During the First 21 Days after Birth
The amount of milk feeding was recorded for each patient each day, beginning on the day of birth and ending on day 21. This was used to calculate the daily enteral calories/kg birth weight. The volume of any emesis estimated by the bedside nurse or gastric residual that was not returned to the subject was subtracted from the enteral intake for this calculation. We made this correction in an attempt to approximate the daily net milk intake. For the comparison patients we recorded only the birth weight, the gestational age, and the daily net milk intake, beginning on the day of birth and ending on day 21.
Statistical Considerations
Descriptive statistics of the gestational ages and birth weights of the experimental and comparison groups were determined using Microsoft Excel. The primary study outcome was the net enteral calories taken over the first 3 weeks of life. Calculations were expressed as calories/kg of birth weight/day. Birth weight was used uniformly to standardize the comparisons. The caloric density of human milk was taken as 0.67 cal/ml even though some patients had human milk fortifier added, or (in two instances) were fed 24-cal/oz formula during the later part of the 21-day-study period. The participating hospitals had no uniform guidelines regarding when to add human milk fortifier or 22-or 24-cal/oz formulas. Also, none of the hospitals measured the caloric content of the human milk used. Therefore, to avoid confusion due to practice variations and variation in caloric density of human milk, we thought it best to uniformly calculate all milk intake as 0.67 kcal/ ml. Since the outcome of interest (calories/kg/day) was not parametrically distributed, those values were expressed as median and range and the Mann-Whitney U test was used to assess the likelihood of identity between values from the experimental vs comparison groups.
RESULTS
The test solution recipients had birth weights of 964±119 g (mean±SD) and gestational ages of 28.3±1.2 weeks. The first five subjects (Table 1) were studied in Florida and the second five in Utah. The birth weights and gestational ages were similar to those of the comparison neonates (1006±151 g and 28.2±1.9 weeks; Table 1 ). All 10 comparison neonates were in Utah. The first dose of the experimental solution was administered at an average of 27 hours after birth (range, 4 to 45). It was given by oral-gastric infusion every 3 hours for an average of 9.9 days (range, 4 to 14). In seven of the 10 recipients, all of the scheduled experimental solution administrations were given every three hours without fail. However in three, one or more of the doses were either held intentionally (subjects 1, 3, and 10) or skipped inadvertently (two doses in subject 3) during the 14 days of study administration. In patients 1 and 3 large gastric prefeeding residuals resulted in withholding two doses of the test solution. Patient 10 had no feeding intolerance detected, but all feedings (including the test solution) were held during a 48-hour period on days of life 13 and 14 because of a ''rule out sepsis'' episode (coagulase negative staphylococcus subsequently grew from the blood cultures).
Among the test solution recipients, the first milk feedings were begun at an average of 74 hours (range, 18 to 144) after birth (Table 1) . This was similar to the timing of the first milk feedings among the comparison patients (79 hours; range, 18 to 168). When milk feedings were given to the test solution recipients they were mixed with the test solution. Eight of the 10 study patients had human milk provided by their mothers; the other two received Similac Special Care (Ross Laboratories, Columbus, OH). Seven of the comparison patients had human milk provided by their mothers and three received a variety of preterm infant formulas. Milk feeding volumes were increased by daily decisions of the attending neonatologist.
The test recipients reached 80 ml/kg of milk feedings 11.8 days after birth (range, 5 to 21 days; Table 1 ). The comparison subjects reached 80 ml/kg of milk feedings 20.2 days after birth (range, 4 to 42 days, p ¼ NS). None of the 20 patients developed radiographically proven necrotizing enterocolitis. Feedings were withheld (NPO) for periods of 24 hours or more among two of the 10 test solution recipients (patients 1 and 10). Patient 1 had feedings withheld because of large prefeeding gastric residuals. Patients 10 had feedings withheld as part of a ''rule out sepsis'' episode on days of life 13 and 14. Seven of the 10 comparison patients had feeding withheld for periods of 24 hours or more Table 2 ). In all 20 subjects, the body weight increased from the day of birth to the 21st day of life. On day 21 the test recipients weighed 128% of birth weight and the comparison group weighed 119% of birth weight (Table 2 ).
DISCUSSION
Attempts to reduce feeding intolerance among VLBW neonates have met with variable success.
14 On the premise that enhancing gastric motility would be useful, erythromycin administration has been tested. However, most studies, including the recent trial by ElHennawy et al., 15 suggest that this treatment is not generally useful in reducing feeding intolerance in this population.
Human milk is generally tolerated better among VLBW neonates than is formula feeding. 16 However, human milk is not available for all VLBW neonates, and small, ill patients who have been enterally fasted for several days sometimes have feeding intolerance even with human milk. Mihatsch et al. tested a hydrolyzed protein preterm formula, among VLBW neonates for whom human milk was not available. Indeed, they found less feeding intolerance using this approach, but the authors pointed out that it is not clear that such formulas meet the nutritional needs of VLBW neonates and they cautioned that long-term studies are needed. 17 Providing minimal enteral nutrition has been used among VLBW neonates as a means of avoiding disuse atrophy of the small bowel mucosa and thereby improving feeding tolerance. 18, 19 Using an experimental model, Owens et al. 20 observed that minimal enteral nutrition did indeed result in maturation of intestinal motor function but had little beneficial effect on the small bowel mucosa.
Functional atrophy of the small bowel mucosa can become marked within only 2 days of complete enteral fasting. 4 In utero, the fetal intestinal mucosa appears to be maintained, at least in part, by swallowing amniotic fluid. Failure to swallow amniotic fluid results in disorganized and rudimentary small bowel mucosa. 21 It was once believed that the physical act of swallowing amniotic liquid was the cause of the normal development of the fetal intestinal mucosa, but the studies of Karnak et al. 22 and Trahair and Harding 23 showed that the benefit comes from the enterocyte growth factors within the amniotic fluid not the volume of liquid.
Maheshwari 24 recently reviewed the human enterocyte growth factors and their mechanisms of action and reported that these factors are also found in human colostrum and in human milk. Of the growth factors found abundantly in human amniotic fluid, only erythropoietin and granulocyte colony-stimulating factor have been approved by the US Food and Drug Administration as recombinant proteins. Erythropoietin was first recognized for its antiapoptotic action on erythrocyte progenitors, but it has been subsequently found to have many nonerythropoietic functions during human fetal development. These include that of a central nervous system neuroprotectant and as an antiapoptotic factor enhancing development of the fetal gastrointestinal mucosa. 25 Similarly, granulocyte colony-stimulating factor was first recognized for its capacity to support the clonal maturation of neutrophils but it has subsequently been found to also have important developmental actions on fetal enterocytes. 26 The normal mid and third trimester fetus swallows 200 to 300 ml of amniotic fluid per kg body weight each day. We reasoned that if we used concentrations of recombinant erythropoietin and recombinant granulocyte colony-stimulating factor that were 10-fold higher than that found in amniotic fluid, and reduced the volume administered 10-fold, from 200 to 20 ml/kg/day, the luminal surface of the small bowel would be exposed to approximately the same amounts of these factors it would normally ''see'' in utero. We reasoned further that providing this solution enterally to VLBW infants during the first days of life (when they would otherwise be NPO) might help preserve the small bowel mucosa and thereby reduce feeding intolerance once milk feedings were introduced.
We realize that it cannot be determined, from the present study, whether this test solution indeed reduces feeding intolerance among VLBW neonates. Without being randomized and blinded, the nurses and neonatologists could have unconsciously effected care to make the test solution seem more successful. Also, whenever a study occurs, care can improve, and it is possible that the attention given the neonates who received the test solution, not the test solution itself, improved their feeding outcome. However, we do conclude that this test solution can likely be given to VLBW neonates for periods up to 14 days without a high incidence of significant short-term adverse effects. We also conclude that the information on enteral intake of these study subjects will be useful in planning a randomized trial. Moreover, the results of this pilot study suggest that a randomized trial to test the effectiveness of this solution in preventing feeding intolerance would be worthwhile.
